Drug intelligence / Profile preview

MMI-175

Development stage: Preclinical
Modality: Peptides, Small Molecules

Overview

MMI-175 is an experimental small molecule hybrid peptide with the molecular formula C38H62N6O8 and a molecular weight of approximately 731 Da. It has been investigated as a β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, which is a target for the treatment of Alzheimer's disease. BACE1 inhibitors are designed to reduce the production of amyloid-beta peptides implicated in Alzheimer's pathology. There are no approved indications or marketed formulations for this compound, and it remains at an early stage of development[1][3][7].

Targets

BACE1 (Beta-site APP-cleaving enzyme 1)

Beyond the preview

Go deeper on MMI-175.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MMI-175.

Explore the full profile